Dr. Tanya R. Bilchik, MD

Dr. Bilchik practices at Yale Medicine in New Haven, Connecticut.

Dr. Bilchik's NPI, 1881668101, was assigned on February 14, 2006. Dr. Bilchik holds Connecticut license 030113.

Dr. Bilchik's primary practice is Yale Medicine, at 50 Division St, New Haven, CT 06511 in South Central Ct County. The practice phone is (203) 785-2140.

Dr. Bilchik's primary practice is Yale Medicine in New Haven, Connecticut. Dr. Bilchik is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Bilchik to 3 more group practices and clinics, 3 medical groups, 1 physician office and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bilchik practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Bilchik's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Bilchik is licensed in Connecticut.

CMS data shows 10,597 Medicare services from Dr. Bilchik across 3 procedure codes in 2024, for 68 Medicare patients. Medicare paid $58,409 for them. Every service was in an office.

CMS counts 68 Medicare patients who saw Dr. Bilchik in 2024. The largest group is 65 to 74, with 33 patients. 71% of them have high cholesterol, and 59% have arthritis. 21% are also on Medicaid. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bilchik's median patient age at 54, with 83% women.

In 2024, Dr. Bilchik wrote 1,335 Medicare Part D claims for 165 patients. 60% of them were for generic drugs. CMS names the drug for 1,210 of them, across 32 drugs with 11 or more claims each, at $546,416 in total drug cost. In 2023, CMS named 1,047 claims across 26 drugs.

Dr. Bilchik accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bilchik as offering telehealth.

Dmand AI links 3 papers to Dr. Bilchik, published from 2014 to 2024. The most frequent topics are Migraine Disorders. Dr. Bilchik's most frequent co-authors are Peter J. McAllister, MD, David W. Dodick, MD and Deena Kuruvilla, MD.

Dmand AI links Dr. Bilchik to 1 clinical trial. Conditions studied include Migraine without Aura and Migraine with Aura.

CMS Open Payments shows 1,382 general payments to Dr. Bilchik from 33 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 76% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $129,845. It also lists 2 research payments totaling $1,016 in 2017.